AdagrasibasibpembrolizumabsotorasibBI-2493G12CidocetaxeldaraxonrasibAZD4785RMC-7977
…d OS of 13.4 months,38 39 leading to full FDA approval in 2024. Adagrasib has also shown modest activity in PDAC (ORR 33%, PFS 5.4 months…
8articles mentioning drugs
32drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: sotorasib ×
sotorasib
This drug is selected. Its supporting articles are shown below.
Articles mentioning sotorasib
8 articles · page 1 of 1osimertinibcrizotinibsotorasibatezolizumabdurvalumablorlatinibosimertinib-treated
…ring may help identify patients who could benefit from extended osimertinib therapy, although further clinical validation is warranted.ctDN…
sotorasibPD-L1iAMG-510non-small cell lung cancer
…oring antitumor immunity and re-sensitizing resistant tumors to sotorasib treatment.Conclusions These results identify the PD-L1-driven i…
trametinibsotorasibhemorrhagic strokeBrain arteriovenous malformations (bAVMs)
…lls demonstrated significant ERK phosphorylation reduction with trametinib (IC 50=12.3 nM) and sotorasib (IC50=38.7 nM).Conclusions This s…
sotorasibramucirumabdocetaxelARPIscancerCommon Sense Oncology initiativeFDANational Comprehensive Cancer Networkhigh-risk hormone-sensitive prostate cancerLMICs+3 more
… rather than to high-cost agents with marginal efficacy such as sotorasib or ramucirumab.Third, it is unacceptable to use inferior contro…
ZoldonrasibSotorasibSMITRIM7
…d outperformed other KRAS pathway inhibitors like Sotorasib and Zoldonrasib, without selectivity to specific KRAS mutations. TRIM7 specific…
sotorasibovarian cancermetastatic ovarian serous adenocarcinoma
…e, showing an excellent durable response to KRAS G12C inhibitor sotorasib at reduced dose of 240 mg oral daily for over 26 months and ong…
MRTX1257MRTX849AMG510adagrasibsotorasibMC38 colon cancerKRASG12C Lewis lung cancerKRASG12C cancer
…tors for KRAS G12C, AMG510 (sotorasib), MRTX849 (adagrasib) and MRTX1257, all displayed potent cytotoxicity to cancer cells harboring KR…